Study on effect of Aspirin on permanent hemodialysis catheters patency rate

Study on the effect of Aspirin on patency rate of permanent hemodialysis catheters in ESRD patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221220056873N1

Enrollment

Registered

2023-04-18

Start date

2023-04-17

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

end stage renal disease. Chronic kidney disease, stage 5

Interventions

Intervention 1: Intervention group: Oral aspirin 80 milligram tablet (from Jalinous company) will be taken daily for 1 year after right jugular permanent catheter placement, and the patency of the pat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: End stage kidney disease(ESRD) patients No history of psychiatric illness Consent to take the medication Right jugular permanent hemodialysis catheter Ability to communicate socially

Exclusion criteria

Exclusion criteria: Previous right jugular catheter Bleeding disorders history

Design outcomes

Primary

Measure	Time frame
Permanent hemodialysis catheter patency rate. Timepoint: Evaluating the catheters patency 6 and 12 months after the placement and aspirin prophylaxis. Method of measurement: The criterion for the proper functioning catheter is patients complete hemodialysis session using 200 cc per minute speed, which is confirmed by the complete dialysis checklist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Farshad Zeinali Baghini

Gorgan University of Medical Sciences

Mfzb0731@gmail.com+98 21 2247 5984

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026